News Archive

Our latest announcements or presentations are available by selecting the desired News Type.

Announcements can be further filtered by topic using the News Topic check boxes.

 

The full text of all announcements are available for download in the form of PDF files.  For convenience, the text of some announcements have been partially or fully rendered as web pages.  Should any inconsistencies exist, the PDF version shall prevail.

News Type
Presentations
RNS Announcements
News Topics
Commercial Platform
Group
Innovation Platform
Regulatory Notice
1
2
3456
found Documents: 263
London: Friday, October 4, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated an international Phase I/Ib study of HMPL-523, its novel spleen tyrosine kinase (“Syk”) inhibitor, in patients with relapsed or refr
Read More
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION   London: Monday, September 30, 2019: Hutchison Chin
Read More
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION   London: Monday, September 30, 2019: Hutchison Chin
Read More
Press Release – Surufatinib achieved primary endpoint, reducing the risk of progression or death by 67% in patients with non-pancreatic neuroendocrine tumors (“NET”) in the Phase III SANET-ep study – – Preparations underway for the potent
Read More
– Late-Breaking Abstract of the positive SANET-ep Phase III trial of surufatinib in patients with non-pancreatic neuroendocrine tumors (“NET”) to be presented – – Conference call and webcast with lead trial investigators to be held on Mond
Read More
London: Wednesday, September 18, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) shares additional analyses from three completed and ongoing clinical studies of fruquintinib and savolitinib at the 22nd Annual Meeting of the C
Read More
London: Tuesday, September 3, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will participate in a fireside chat at Morgan Stanley 17th Annual Global Healthcare C
Read More
London: Tuesday, September 3, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated an international Phase I/Ib study of HMPL-689, its novel, highly selective and potent small molecule phosphoinositide-3 kinase delta
Read More
London: Friday, August 23, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a Phase I study of HMPL-523, its novel spleen tyrosine kinase (“Syk”) inhibitor, in patients with immune thrombocytopenia (“ITP”
Read More
London: Tuesday, July 30, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces its unaudited financial results for the six months ended June 30, 2019 and provides updates on key clinical programs.  Major highlight
Read More
London: Wednesday, July 3, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2019 on Tuesday, July 30, 2019 at 7:00 am British Summer Time (BST) (2:00 pm
Read More
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION London: June 28, 2019: Hutchison China MediTech Limited (“
Read More
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION London: June 27, 2019: Hutchison China MediTech Limited (“
Read More
London: Friday, June 14, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that the independent Data Monitoring Committee (“IDMC”) of the Phase III pivotal study of surufatinib in advanced neuroendocrine tum
Read More
London: Wednesday, May 29, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that the ordinary resolution and special resolution put to its Extraordinary General Meeting (“EGM”) held on May 29, 2019 were dul
Read More
London: Friday, May 3, 2019: Hutchison China MediTech Limited (“Chi-Med” or “Company”) (AIM/Nasdaq: HCM) today announces that an Extraordinary General Meeting (“EGM”) is to be held at 11:00 a.m. London time on Wednesday, May 29, 2019. An
Read More
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Hong Kong: Monday, April 15, 2019: Hutchison China MediTech
Read More
London: Friday, March 29, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a registration-enabling Phase IIb/III study comparing surufatinib (HMPL-012 or sulfatinib) with capecitabine in patients with advanced
Read More
Press Release London: Thursday, March 28, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will share further data on the savolitinib development programs in lung cancer at the American Association of Cancer Research (AACR)
Read More
London: Thursday, March 21, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that its 2018 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy have been posted to shareholders
Read More
London: Monday, March 11, 2019: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today published the Form 20-F for the financial year ended December 31, 2018. This is available for viewing at http://www.rns-pdf.londonstockexchange.com/r
Read More
London: Monday, March 11, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces its audited financial results for the year ended December 31, 2018 and provides updates on key clinical programs. Video webcas
Read More
London: Tuesday, February 12, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announced the availability of preliminary results from the Phase II CALYPSO study of the savolitinib / Imfinzi® (durvalumab) combination in
Read More
London: Friday, February 8, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will announce its final results for the year ended December 31, 2018 on Monday, March 11, 2019 at 7:00 am Greenwich Mean Time (GMT). An analyst pr
Read More
Press Release London: Monday, January 7, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will present at the 37th Annual JP Morgan Healthcare Conference on Wednes
Read More
– Chi-Med acquires right to determine & conduct all future life cycle indication development of fruquintinib monotherapy as well as innovative combinations in China –  – Chi-Med to assume all development costs of life cycle indications in
Read More
– Global SAVANNAH study of savolitinib / Tagrisso®combination in MET+ EGFRm NSCLC underway. Data presented at ESMO 2018 showedMET-amplification among the most frequent mechanisms of acquired resistance to AstraZeneca’s Tagrisso® – – China
Read More
London: Thursday, November 29, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) entered into four collaboration agreements to evaluate the safety, tolerability and efficacy of Chi-Med’s surufatinib (HMPL-012 or sulfatinib) a
Read More
London: Monday, November 26, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces the first commercial launch of fruquintinib capsules (Elunate®) with the initiation of product sales in China. Elunate® is for the
Read More
– Trial did not meet the primary endpoint of overall survival despite improvement in progression-free survival – London: Friday, November 16, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces the outcome of
Read More
London: Thursday, October 18, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a Phase I study of HMPL-523, its novel spleen tyrosine kinase (“Syk”) inhibitor, in combination with azacitidine, an approved nuc
Read More
– Fruquintinib capsules provide a new oral treatment option for patients with metastatic colorectal cancer and will be marketed as Elunate® – – Elunate® data published in JAMA demonstrated increased overall survival versus placebo – – F
Read More
London: Friday, July 27, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces its unaudited financial results for the six months ended June 30, 2018 and updates shareholders on key clinical programs. Fruquinti
Read More
London: Monday, July 23, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a Phase Ib/II proof-of-concept study of sulfatinib in pancreatic neuroendocrine tumors (“NET”) patients and in biliary tract cancer (
Read More
London: Friday, June 29, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2018 on Friday, July 27, 2018 at 7:00 am British Summer Time (BST). An analy
Read More
Press Release – Chi-Med makes additional FRESCO presentations at ASCO 2018, following oral presentation at ASCO 2017 showing that study met all endpoints with a manageable safety profile and lower off-target toxicities compared to other targeted t
Read More
Press Release   London: Friday, May 11, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announced today that Christian Hogg, Chief Executive Officer, will present at the Bank of America Merrill Lynch 2018 Health Care Confe
Read More
London: Monday, March 26, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that its 2017 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy have been posted to shareholders.
Read More
Hutchison China MediTech Limited (“Chi-Med”) Reports Final Results for the Year Ended December 31, 2017 and Updates Shareholders on Key Clinical Programs Group: Year of major progress; results in line with guidance Group revenue up 12% to $
Read More
London: Tuesday, March 6, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a Phase Ib/II proof-of-concept study of epitinib in glioblastoma patients with epidermal growth factor receptor (“EGFR”) gene amplifi
Read More
London: Tuesday, February 13, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has completed patient enrollment of FALUCA, its Phase III pivotal trial of fruquintinib in advanced, third-line, non-small cell lung cancer (“NSC
Read More
London: Friday, December 15, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated the United States Phase I bridging clinical trial of fruquintinib. Fruquintinib is a highly selective and potent oral inhibitor of vas
Read More
London: Tuesday, October 31, 2017: Hutchison China MediTech Limited (“Chi‑Med”) (AIM/Nasdaq: HCM) has initiated FRUTIGA, a pivotal Phase III clinical trial of fruquintinib in combination with paclitaxel (Taxol®) for the treatment in advanced g
Read More
London: Monday, October 30, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announced today the closing of its underwritten public offering of American Depositary Shares ("ADSs") on the Nasdaq Global Select Market, previously
Read More
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION London: Friday, October 27, 2017: Hutchison China MediTech L
Read More
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION London: Wednesday, October 25, 2017: Hutchison China MediTec
Read More
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION London: Tuesday, October 24, 2017: Hutchison China MediTech
Read More
– Data for savolitinib in combination with Tagrisso® or Iressa® presented at World Conference on Lung Cancer –  – New data give insights into disease progression and potential next-generation treatment strategies in patients with EGFR-muta
Read More
Press Release – Fruquintinib in combination with Iressa® (gefitinib) shows promising efficacy and an acceptable safety profile – – Further validation of strong potential for use of fruquintinib in combination with other cancer therapies du
Read More